文献速递外周动脉疾病

术前西洛他唑与CLTI血管腔内血运重建后生存改善相关

Pre-operative Cilostazol in Patients with Chronic Limb Threatening Ischaemia Associated with Improved Survival after Endovascular Revascularisation.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2025-08-20

该回顾性队列研究基于Vascular Quality Initiative登记数据,纳入2015至2021年接受择期外周血管腔内治疗的CLTI患者,比较术前使用西洛他唑组与未使用组。结果显示西洛他唑组五年全因死亡风险显著降低(HR 0.56,95%CI 0.5-0.6,P<.001),围术期截肢率亦较低(OR 0.69,95%CI 0.6-0.8,P<.001)。

要点

  • 术前使用西洛他唑与CLTI患者EVT后五年全因死亡风险降低相关。
  • 西洛他唑组围术期截肢率低于未使用组,其余围术期结局无差异。
  • 结论支持在高危CLTI人群中进一步开展前瞻性研究验证西洛他唑获益。

核心结论

  • CLTI患者EVT术前使用西洛他唑与长期生存改善及围术期截肢率降低相关。

研究设计与样本

  • 回顾性队列研究,使用Vascular Quality Initiative登记数据,纳入2015至2021年接受择期外周血管腔内治疗的患者,按术前西洛他唑使用分为PC组与NPC组,并进行倾向评分调整。

主要发现

  • PC组五年全因死亡风险显著低于NPC组(HR 0.56,95%CI 0.5-0.6,P<.001)。
  • PC组围术期截肢率低于NPC组(OR 0.69,95%CI 0.6-0.8,P<.001)。
  • 两组其他围术期结局无差异。

临床怎么用

  • 对于接受EVT的CLTI患者,可考虑术前评估并使用西洛他唑以潜在改善长期生存并降低围术期截肢风险。

局限性

  • 为回顾性队列研究,存在残余混杂可能,需前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The study aimed to assess the effect of pre-operative cilostazol on long term survival and peri-operative outcomes in patients with chronic limb threatening ischaemia (CLTI) undergoing endovascular therapy (EVT). METHODS: This retrospective cohort study used the Vascular Quality Initiative registry, including a propensity score adjusted cohort of patients who underwent elective peripheral vascular interventions between 2015 and 2021. Patients were categorised based on pre-operative cilostazol use: cilostazol (PC) group and no cilostazol (NPC) group. The primary outcome was long term (five years) all cause mortality, with secondary outcomes including peri-operative amputation, cardiac complications, and thrombotic or embolic events. RESULTS: There were 55 457 patients in the NPC group and 3 173 patients in the PC group who underwent EVT and were included in the final cohort. The PC group showed statistically significantly higher long term survival than the NPC group (hazard ratio 0.56, 95% confidence interval [CI] 0.5 - 0.6; p < .001) over a follow up period of five years. The PC group also demonstrated lower rates of peri-operative amputation compared with the NPC group (odds ratio 0.69, 95% CI 0.6 - 0.8; p < .001). No other differences were found for peri-operative outcomes between groups. CONCLUSION: Pre-operative cilostazol use in patients with CLTI undergoing EVT was associated with improved long-term survival and reduced peri-operative amputation rates. These findings suggest a potential benefit of cilostazol in this high-risk population, justifying further dedicated, prospective studies.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Sansosti AA, Choi B, Munoz J, et al. Pre-operative Cilostazol in Patients with Chronic Limb Threatening Ischaemia Associated with Improved Survival after Endovascular Revascularisation. Eur J Vasc Endovasc Surg. 2025. PMID: 40845964. doi:10.1016/j.ejvs.2025.08.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。